HELICAL-FUSION
13.5.2024 16:01:32 CEST | Business Wire | Press release
Helical Fusion has entered a partnership agreement with the National Institute for Fusion Science (NIFS) in March 2024. NIFS has established the "HF Collaboration Research Group" with activities starting in April, special experimental research space has been dedicated onsite at NIFS, which already houses the world's largest superconductor and fusion experimental facility, for Helical Fusion.
With its support from NIFS, Helical Fusion will accelerate the realization of the world's first commercial fusion reactor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507957768/en/
Co-Founder, CEO of Helical Fusion Takaya Taguchi (left) and Chief of Industry-Academia-Government Coordination Section of NIFS Ryo Yasuhara (right), shake hands at NIFS in Toki-City, Gifu, Japan. (Photo: Business Wire)
[Background]
Against the backdrop of a projected global population increase of ~1.7 billion by 2050* and the corresponding surge in worldwide electricity demand, conventional power generation methods alone are expected to struggle to meet these needs. Fusion power offers a clean and safe alternative, utilizing inexhaustible fuel supplies, such as seawater, and thus holds the promise as a technology capable of fundamentally addressing these global challenges. With Japan's energy self-sufficiency rate at a low of 13.3% and fossil fuel dependency still exceeding 80%**, research and development efforts have been underway to secure future baseload power sources.
NIFS, boasting one of the world's largest fusion experimental facilities, the Large Helical Device (LHD) in Gifu prefecture, Japan, has been at the forefront of research into helical-type fusion reactors since its establishment by the government in 1989, yielding remarkable results on a global scale. Building on NIFS's expertise, Helical Fusion was founded in 2021, leveraging the speed and agility typical of startups to lead the development of the world's first commercial steady fusion reactor.
While individual collaborative research efforts have been ongoing with NIFS, the firm establishment of the "HF Collaboration Research Group" going forward, as well as a dedicated experimental space, marks a significant step toward strengthening cooperation, aimed towards the early social implementation of fusion energy.
Reference: for the press release from the National Institute for Fusion Science, click here)
[Comment from Mr. Takaya TAGUCHI (Co-founder, CEO of Helical Fusion)]
Helical Fusion is a startup born from the wealth of cutting-edge research achievements and expertise accumulated by NIFS over more than 30 years. We have conducted numerous joint research projects with NIFS in areas such as high-temperature superconducting magnets and liquid metal blankets. Given the growing global expectations of the helical-stellarator fusion approach, to operate as a steady-state commercialized reactor, we have further strengthened our collaboration to accelerate development by establishing this department, as well as setting up dedicated experimental research space. This will not only accelerate joint research but also advance progress in our proprietary tech development, particularly in the field of high-temperature superconducting magnets. We express our feelings of appreciation to the NIFS team for their cooperation and strive to meet everyone's expectations by furthering our efforts in research and development, so as to lead development with global competition towards an operation ready, steady-state fusion reactor. Furthermore, we aim to contribute to the creation of industries where Japan's proud technologies, from basic research to high-end manufacturing, can be leveraged.
[Comment from Mr. Ryo Yasuhara (Chief of Industry-Academia-Government Coordination Section, NIFS)]
The National Institute for Fusion Science has established a collaborative research department with Helical Fusion, called the "HF Collaboration Research Group", in order to conduct research and development for the practical implementation of helical-type fusion reactors. This joint research group will mainly contribute the specialized knowledge and resources of Helical Fusion and NIFS to conduct research activities aimed at realizing helical-type fusion reactor. NIFS aims to contribute to the advancement of fusion science and the establishment of a broad foundation for science and technology through research activities at the highest global standards. We hope that the achievements obtained in this research group will be a step towards realizing sustainable energy.
*“World Energy Outlook 2023” International Energy Agency (https://www.iea.org/reports/world-energy-outlook-2023)
**”The white paper on energy usage 2022”, Agency for Natural Resources and Energy (https://www.enecho.meti.go.jp/about/whitepaper/2023/pdf/)
[About Us]
Helical Fusion is a Japanese start-up company aiming at the social implementation of fusion energy with a magnetic confinement fusion reactor.
Various fusion methods have been developed in the world over the past 60 years as a next generation energy source.
In Japan, the helical fusion method, which uses a superconducting helical coil with a double-helical structure similar to DNA to stably confine high-temperature plasma, has been developed and nurtured to a great extent. We are aiming to develop the world's first steady-state fusion reactor by incorporating more advanced technologies into the helical-stellarator type fusion reactor.
Additionally, Helical Fusion's proprietary development efforts, including high-temperature superconducting magnet vital for realizing commercial reactors, have received Japanese SBIR grant funding, further accelerating progress towards commercialization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507957768/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 14:00:00 CEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
